TCF7L2 polymorphism is associated with low nitric oxide release, endothelial dysfunction and enhanced inflammatory response after myocardial infarction
Cintra R, Moura F, Carvalho L, Daher M, Santos S, Costa A, Figueiredo V, Andrade J, Neves F, Quinaglia e Silva J, Sposito A, Group O. TCF7L2 polymorphism is associated with low nitric oxide release, endothelial dysfunction and enhanced inflammatory response after myocardial infarction. BBA Clinical 2016, 5: 159-165. PMID: 27213136, PMCID: PMC4865630, DOI: 10.1016/j.bbacli.2016.03.010.Peer-Reviewed Original ResearchC-reactive proteinFlow-mediated dilationST-elevation MIInterleukin-2Myocardial infarctionInsulin secretionCapacity of insulin secretionNitric oxideAssociated with lower insulin secretionHigher 30-day mortalityNon-diabetic STEMI patientsNon-diabetic patientsT allele carriersTranscription factor 7-like 2Influence clinical outcomesEnhanced inflammatory responseTCF7L2 gene polymorphismPlasma interleukin-2Short-term mortalityEndogenous insulin secretionNitric oxide releaseLower insulin secretionExogenous insulin administrationNitric oxide changesRs7903146 polymorphism